NCT02270606View on ClinicalTrials.gov

Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 4, 2014

Primary Completion Date

May 14, 2018

Study Completion Date

May 13, 2021

Conditions
Mucinous Adenocarcinoma of the RectumRecurrent Rectal CancerSignet Ring Adenocarcinoma of the RectumRectal AdenocarcinomaStage IIA Rectal CancerStage IIB Rectal CancerStage IIC Rectal CancerStage IIIA Rectal CancerStage IIIB Rectal CancerStage IIIC Rectal Cancer
Interventions
RADIATION

intensity-modulated radiation therapy

Undergo IMRT

DRUG

fluorouracil

Given IV

DRUG

oxaliplatin

Given IV

DRUG

leucovorin calcium

Given IV

PROCEDURE

therapeutic conventional surgery

Undergo total mesorectal excision

Trial Locations (1)

23219

Virginia Commonwealth University/Massey Cancer Center, Richmond

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Virginia Commonwealth University

OTHER

NCT02270606 - Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer | Biotech Hunter | Biotech Hunter